Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: Minocycline

Pharmacotherapy

Volumn 30, Issue 7 PART 2, 2010, Pages

  Hess, David C ^a   Fagan, Susan C ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Acute ischemic stroke; Minocycline; MMP 9; PARP 1; Tissue plasminogen activator

Indexed keywords

BIOLOGICAL MARKER; DOXYCYCLINE; FIBRINOLYTIC AGENT; GELATINASE B; MINOCYCLINE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TETRACYCLINE; TIGECYCLINE; TISSUE PLASMINOGEN ACTIVATOR;

ABSENCE OF SIDE EFFECTS; ACNE; ACUTE DISEASE; ADJUVANT ARTHRITIS; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONVALESCENCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PERIODONTAL DISEASE; RECANALIZATION; REPERFUSION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEX DIFFERENCE; SYMPTOM;

ANIMALS; BRAIN ISCHEMIA; DRUG REPOSITIONING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MINOCYCLINE; NEUROPROTECTIVE AGENTS; RATS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77954699101     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.pt2.55S     Document Type: Review

References (66)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Reeves MJ, Arora S, Broderick JP, et al, for the Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell national acute stroke registry. Stroke 2005;36:1232-40.
3. Kleindorfer D, Xu Y, Moomaw CJ, et al. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009;40:3580-4.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
5. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-8.
6. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
7. Bose A, Henkes H, Alfke K, et al. The penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008;29:1409-13.
8. Soares BP, Chien JD, Wintermark M. MR and CT monitoring of recanalization, reperfusion, and penumbra salvage: everything that recanalizes does not necessarily reperfuse! Stroke 2009;40:S24-7.
9. De Silva DA, Fink JN, Christensen S, et al. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke 2009;40: 2872-4.
10. Ames A III, Wright RL, Kowada M, et al. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 1968;52:437-53.
11. del Zoppo GJ, Schmid-Schonbein GW, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991;22:1276-83.
12. Hallenbeck JM, Dutka AJ, Tanishima T, et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 1986;17:246-53. (Pubitemid 16125248)
13. Garcia JH, Liu KF, Yoshida Y, et al. Brain microvessels: factors altering their patency after the occlusion of a middle cerebral artery (Wistar rat). Am J Pathol 1994;145:728-40. (Pubitemid 24285979)
14. Yemisci M, Gursoy-Ozdemir Y, Vural A, et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009;15:1031-7.
15. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977;8:51-7.
16. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005;36:2311-20.
17. Wintermark M, Flanders AE, Velthuis B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006;37:979-85.
18. Muir KW, Buchan A, von Kummer R, et al. Imaging of acute stroke. Lancet Neurol 2006;5:755-68.
19. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-8.
20. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
21. Brown DL, Barsan WG, Lisabeth LD, et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 2005;46: 56-60. (Pubitemid 40916897)
22. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20: 219S-23; panel discussion 224S-8.
23. Leyden JJ, McGinley KJ, Kligman AM. Tetracycline and minocycline treatment. Arch Dermatol 1982;118:19-22.
24. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebocontrolled trial. MIRA trial group. Ann Intern Med 1995;122: 81-9.
25. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998;95:15769-74. (Pubitemid 29018775)
26. Yrjanheikki J, Tikka T, Keinanen R, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999;96:13496-500.
27. Wang CX, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2002;2:2. (Pubitemid 38729088)
28. Wang CX, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res 2003;963:327-9. (Pubitemid 36126315)
29. Nagel S, Su Y, Horstmann S, et al. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res 2008;1188:198-206. (Pubitemid 350296055)
30. Yenari MA, Xu L, Tang XN, et al. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 2006;37:1087-93.
31. Fagan SC, Edwards DJ, Borlongan CV, et al. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-51.
32. Xu L, Fagan SC, Waller JL, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004;4:7. (Pubitemid 38729097)
33. Machado LS, Sazonova IY, Kozak A, et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke 2009;40:3028-33.
34. Murata Y, Rosell A, Scannevin RH, et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008;39:3372-7.
35. Machado LS, Kozak A, Ergul A, et al. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 2006;7:56.
36. Gieseler A, Schultze AT, Kupsch K, et al. Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem Pharmacol 2009;77:888-96.
37. Haroon MF, Fatima A, Scholer S, et al. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol Dis 2007;28:237-50.
38. Theruvath TP, Zhong Z, Pediaditakis P, et al. Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition. Hepatology 2008;47:236-46.
39. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 2006;103: 9685-90.
40. Petrilli V, Herceg Z, Hassa PO, et al. Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest 2004;114:1072-81.
41. Moroni F, Chiarugi A. Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J 2009;276:36-45.
42. Moroni F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin Pharmacol 2008;8:96-103. (Pubitemid 351168695)
43. Andrabi SA, Kim NS, Yu SW, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A 2006;103: 18308-13.
44. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci 2009;14:1116-28.
45. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009;218:193-202.
46. Kauppinen TM, Suh SW, Berman AE, et al. Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 2009;29:820-9.
47. McCullough LD, Zeng Z, Blizzard KK, et al. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 2005;25:502-12.
48. Li J, McCullough LD. Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab 2009;29:670-4.
49. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-6. (Pubitemid 34204013)
50. Montaner J, Rovira A, Molina CA, et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003;23:1403-7. (Pubitemid 38018258)
51. Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008;39:1121-6. (Pubitemid 351440679)
52. Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001;32: 2762-7.
53. Heo JH, Kim SH, Lee KY, et al. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003;34:e48-50.
54. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9:1313-17. (Pubitemid 37279856)
55. Horstmann S, Kalb P, Koziol J, et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003;34:2165-70. (Pubitemid 37099830)
56. Kelly PJ, Morrow JD, Ning M, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the biomarker evaluation for antioxidant therapies in stroke (BEAT-Stroke) study. Stroke 2008;39:100-4.
57. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603. (Pubitemid 36176811)
58. Castellanos M, Sobrino T, Millan M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007;38:1855-9.
59. Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 1993;64:819-27.
60. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD clinical research team. Ann N Y Acad Sci 1999;878:335-46.
61. Greenwald RA. Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann N Y Acad Sci 1994;732:181-98.
62. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308. (Pubitemid 34587139)
63. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-42. (Pubitemid 36622510)
64. Koistinaho M, Malm TM, Kettunen MI, et al. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9- deficient mice. J Cereb Blood Flow Metab 2005;25:460-7.
65. Brown DL, Desai KK, Vakili BA, et al. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733-8.
66. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-10. (Pubitemid 47511461)